EPHA2 and cancer: MEDI-547 is an antibody–drug conjugate (ADC) composed of a human immunoglobulin (Ig) G1 monoclonal antibody directed against EphA2 (known as 1C1) and conjugated on cysteine residues to an auristatin derivative linker-toxin maleimidocaproyl-monomethyl auristatin phenylalanine, intended for delivering chemotherapy drugs directly to EphA2-expressing cancer cells.